Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №11 (2024) > The role of CYP2C19 gene variants in the development of bleeding in patients receiving clopidogrel as part of dual antithrombotic therapy: a clinical case of a patient with coronary heart disease and atrial fibrillation after acute coronary syndrome

The role of CYP2C19 gene variants in the development of bleeding in patients receiving clopidogrel as part of dual antithrombotic therapy: a clinical case of a patient with coronary heart disease and atrial fibrillation after acute coronary syndrome

Valeria A. De , Alexey I. Kochetkov , Karin B. Mirzaev , Sherzod P. Abdullayev , Valeriy A. Konik , Olga D. Ostroumova , Dmitry A. Sychev

For citation:


  • Abstract
  • About the Author
  • References

Abstract

We present a clinical case of a 47-year-old man with coronary heart disease, arterial hypertension, type 2 diabetes mellitus and paroxysmal atrial fibrillation, who was prescribed dual antithrombotic therapy (DAT) – clopidogrel and rivaroxaban, after successful coronary stenting due to acute coronary syndrome (ACS). Not only routine examination was performed, but also the patient underwent pharmacogenetic testing to determine CYP2C19 genetic variants (rs4244285 – *2, rs4986893 – *3, and rs12248560 – *17). Bleeding was assessed retrospectively 17 weeks after acute coronary syndrome on the 1 visit and at follow-up visits (4, 8, 12, and 16 weeks). On the 1 visit the patient complained about nosebleeds and bruising <1 cm in diameter. During follow-up period nosebleeds lasting <10 minutes and bleeding from minor wounds lasting more than 5 minutes were found. All bleedings did not require medical intervention or withdrawal of DAT. According to the results of pharmacogenetic testing, the patient was a carrier of TT genotype of rs12248560, GG genotype of rs4244285, GG genotype of rs4986893 CYP2C19 gene, which corresponds to the phenotype – "ultrarapid metabolizer". This clinical case shows evidence of the association between CYP2C19*17 allele with a higher bleeding risk in patients taking DAT.
Keywords: acute coronary syndrome, atrial fibrillation, clopidogrel, pharmacogenetics, direct oral anticoagulants, CYP2C19, bleeding, adverse drug reactions, case report.

About the Author

Valeria A. De 1 , Alexey I. Kochetkov 1 , Karin B. Mirzaev 1 , Sherzod P. Abdullayev 1 , Valeriy A. Konik 2 , Olga D. Ostroumova 3 , Dmitry A. Sychev 1

1 Russian Medical Academy of Continuous Professional Education, Moscow, Russia

2 nozemtsev Moscow City Clinical Hospital, Moscow, Russia

3 Russian Medical Academy of Continuous Professional Education, Moscow, Russia; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

References

1. Александрова Г.А., Ахметзянова Р.Р., Голубев Н.А. и др. Здравоохранение в России. 2023: Статистический сборник. М., 2023.
Aleksandrova G.A., Akhmetzyanova R.R., Golubev N.A. and others. Healthcare in Russia. 2023: Statistical collection. Moscow, 2023 (in Russian).
2. Клинические рекомендации «Острый коронарный синдром без подъема сегмента ST электрокардиограммы». 2023.
Clinical guidelines «Acute coronary syndrome without ST segment elevation of the electrocardiogram». 2023 (in Russian).
3. Dohi T, Maehara A, Witzenbichler B et al. Etiology, Frequency, and Clinical Outcomes of Myocardial Infarction After Successful Drug-Eluting Stent Implantation: Two-Year Follow-Up From the ADAPT-DES Study. Circ Cardiovasc Interv 2015;8(12):e002447. DOI: 10.1161/ CIRCINTERVENTIONS.114.002447
4. Mozaffarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation 2015;131(4):e29-322. DOI: 10.1161/CIR.0000000000000152
5. Townsend N, Wilson L, Bhatnagar P et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016;37(42):3232-45. DOI: 10.1093/eurheartj/ehw334
6. Lee SH, Jeong MH, Ahn JH et al. Predictors of recurrent acute myocardial infarction despite successful percutaneous coronary intervention. Korean J Intern Med 2022;37(4):777-85. DOI: 10.3904/kjim.2021.427
7. Kikkert WJ, Zwinderman AH, Vis MM et al. Timing of mortality after severe bleeding and recurrent myocardial infarction in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2013;6(4):391-8. DOI: 10.1161/CIRCINTERVENTIONS.113.000425
8. Hwang YJ, Chang HY, Metkus T et al. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study. Drug Saf 2024;47(3):251-60. DOI: 10.1007/s40264-023-01388-z
9. Сычев Д.А., Шпрах В.В., Китаева Е.Ю., Мирзаев К.Б. Полиморфизм генов CYP2C19 и ABCB1, ассоциированный с изменением активности клопидогрела, у больных ишемическим инсультом: клинические и этнические аспекты. Клиническая фармакология и терапия. 2019;28(3): 79-84. DOI: 10.32756/0869-5490-2019-3-79-84
Sychev D.A., Shprakh V.V., Kitaeva E.Yu., Mirzaev K.B. Polymorphism of the CYP2C19 and ABCB1 genes associated with changes in clopidogrel activity in patients with ischemic stroke: clinical and ethnic aspects. Clinical Pharmacology and Therapy. 2019;28(3): 79-84. DOI: 10.32756/0869-5490-2019-3-79-84 (in Russian).
10. Yi X, Wang Y, Lin J et al. Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. Clin Appl Thromb Hemost 2017;23(7):761-8. DOI: 10.1177/1076029616648408
11. Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006;4(4):766-73. DOI: 10.1111/j.1538-7836.2006.01847.x
12. Lee CR, Luzum JA, Sangkuhl K et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther 2022;112(5):959-67. DOI: 10.1002/cpt.2526
13. Spencer FA, Moscucci M, Granger CB et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 2007;116(24):2793-801. DOI: 10.1161/CIRCULATIONAHA.107.694273
14. Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin 2014;32(3):439-55. DOI: 10.1016/j.ccl.2014.04.001
15. Клинические рекомендации «Фибрилляция и трепетание предсердий у взрослых». Минздрав России. 2020.
Clinical guidelines «Atrial fibrillation and flutter in adults». Ministry of Health of the Russian Federation. 2020 (in Russian).
16. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100. DOI: 10.1378/chest.10-0134
17. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012;125(19):2298-307. DOI: 10.1161/CIRCULATIONAHA.111.055079
18. Winter MP, von Lewinski D, Wallner M, et al. Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS – SWITCH study. Sci Rep 2019;9(1):8194. DOI: 10.1038/s41598-019-44673-7
19. Mehran R, Baber U, Steg PG et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382(9906):1714-22. DOI: 10.1016/S0140-6736(13)61720-1
20. Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371(23):2155-66. DOI: 10.1056/NEJMoa1409312

For citation:De V.A., Kochetkov A.I., Mirzaev K.B., Abdullaev Sh.P., Konik V.A., Ostroumova O.D., Sychev D.A. The role of CYP2C19 gene variants in the development of bleeding in patients receiving clopidogrel as part of dual antithrombotic therapy: a clinical case of a patient with coronary heart disease and atrial fibrillation after acute coronary syndrome. Clinical review for general practice. 2024; 5 (11): 49–54 (In Russ.). DOI: 10.47407/kr2024.5.11.00516


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru